Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

Rivero, Antonio; Pérez-Molina, José Antonio; Blasco, Antonio, Javier; Arribas, José Ramón; Asensi, Víctor; Crespo, Manuel; Domingo, Pere; Iribarren, José Antonio; Lázaro, Pablo; Lozano, Fernando; Martínez, Esteban; Moreno, Santiago; Palacios, Rosario; Pineda, Juan Antonio; Pulido, Federico; Rubio, Rafael; Santos, Jesús; Torre, Javier de la; Tuset, Montserrat; Gatell, Josep M.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 36(5): 268-276, mayo 2018. tab, graf
Artigo em Inglês | IBECS (Espanha) | ID: ibc-176567

Documentos relacionados

  1. Fund Black scientists.
  2. From scientific discovery to cures: bright stars within a galaxy.
  3. Revising the a Priori Hypothesis: Systemic Racism Has Penetrated Scientific Funding.
  4. Not All Champions Are Allies in Health Disparities Research.
  5. Philosophies of funding.
  6. Mapping the Mouse Cell Atlas by Microwell-Seq.
  7. Consent document translation expense hinders inclusive clinical trial enrolment.
  8. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
  9. Francis Collins: Reflections on being the NIH Director.
  10. Association of Surgeon Representation on NIH Study Sections With Receipt of Funding by Surgeon-scientists.